Andrew Vernon

9.0k citations

58 papers · 4.7k indexed · 2 hit papers · h-index 34

Impact in

Infectious Diseases top 0.2%
- Tuberculosis Research and Epidemiology
Epidemiology top 0.5%
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections

Papers in

Infectious Diseases 42
- Tuberculosis Research and Epidemiology 39
- HIV/AIDS drug development and treatment 5
Epidemiology 33
- Pneumocystis jirovecii pneumonia detection and treatment 18
- Mycobacterium research and diagnosis 10
- Pneumonia and Respiratory Infections 10

Co-authors: John Jereb Gerald H. Mazurek Stefan Goldberg William J. Burman Kenneth G. Castro Charles A. Peloquin Marc Weiner Michael F. Iademarco
Journals: American Journal of Respiratory and Critical Care Medicine (10 papers)PLoS Medicine (7 papers)Clinical Infectious Diseases (3 papers)Contemporary Clinical Trials (3 papers)Antimicrobial Agents and Chemotherapy (3 papers)
Partner nations: United States Uganda Canada

In The Last Decade

Andrew Vernon

55 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. 2010 · 843 citations

Peers

Countries citing papers authored by Andrew Vernon

Since Specialization

Citations

This map shows the geographic impact of Andrew Vernon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Vernon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Vernon more than expected).

Fields of papers citing papers by Andrew Vernon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Vernon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Vernon. The network helps show where Andrew Vernon may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Vernon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Vernon Line = papers co-authored together Andrew Vernon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Disability Status, Employment, and Access to Vocational Rehabilitation Services Among Rural Veterans with Physical and Mental Health Conditions Journal of Vocational Rehabilitation ·Emre Umucu, M. J. Fitchett, Andrew Vernon, 誠伊原, Shenghui Huang, Beatrice Lee	2025	0
2	Advances in clinical trial design: Weaving tomorrow’s TB treatments PLoS Medicine ·Christian Lienhardt, Andrew Nunn, Richard E. Chaisson, Andrew Vernon, Matteo Zignol, Payam Nahid, Éric Delaporte, Tereza Kasaeva	2020	14
3	Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance PLoS Medicine ·Christian Lienhardt, Andrew Vernon, Marco Cavaleri, Débora Vareiro, Payam Nahid	2019	11
4	Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials Annals of the American Thoracic Society ·Ruth N. Moro, Nigel Scott, Andrew Vernon, Naomi K. Tepper, Stefan Goldberg, Kevin Schwartzman, Chi Chiu Leung, Neil W. Schluger, Robert Belknap, Richard E. Chaisson, Masahiro Narita, Elizabeth S. Machado, Marta López, Jorge Sánchez, Margarita E. Villarino, Timothy R. Sterling	2018	42
5	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial American Journal of Respiratory and Critical Care Medicine ·Susan E. Dorman, Radojka M. Savić, Stefan Goldberg, Jason E. Stout, Neil W. Schluger, Grace Muzanyi, John L. Johnson, Payam Nahid, Emily J. Hecker, Charles M. Heilig, Lorna Bozeman, 제정구 바오로, Ruth N. Moro, William R. Mac Kenzie, Kelly E. Dooley, Eric Nuermberger, Andrew Vernon, Marc Weiner	2014	76
6	The Association between Symptoms and Microbiologically Defined Response to Tuberculosis Treatment Annals of the American Thoracic Society ·Craig M. Hales, Charles M. Heilig, Richard E. Chaisson, Chi Chiu Leung, Kwok Chiu Chang, Stefan Goldberg, Fred M. Gordin, John L. Johnson, Grace Muzanyi, Jussi Saukkonen, Andrew Vernon, Margarita E. Villarino, William J. Burman	2013	18
7	New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Current Opinion in Pulmonary Medicine ·Christian Lienhardt, Andrew Vernon, Mario Raviǵlione	2010	107
8	Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis American Journal of Respiratory and Critical Care Medicine ·Susan E. Dorman, John L. Johnson, Stefan Goldberg, Grace Muzanye, Nesri Padayatchi, Lorna Bozeman, Charles M. Heilig, John Bernardo, Shurjeel Choudhri, J Grosset, Elizabeth Guy, 刘东臣, 黄玉峰, Gina Maltas, Dick Menzies, Eric Nuermberger, Margarita E. Villarino, Andrew Vernon, Richard E. Chaisson	2009	184
9	Relapse Associated with Active Disease Caused by Beijing Strain ofMycobacterium tuberculosis1 Emerging infectious diseases ·William J. Burman, Muhammad Farhan Affendi Mohamad Yunos, Lauren S. Cowan, Lorna Bozeman, Payam Nahid, Lois Diem, Andrew Vernon	2009	38
10	Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis PLoS Medicine ·Dick Menzies, Andrea Benedetti, Anita Paydar, Sarah Royce, Madhukar Pai, William J. Burman, Andrew Vernon, Christian Lienhardt	2009	145
11	Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis American Journal of Respiratory and Critical Care Medicine ·Ian M. Rosenthal, Kathy N. Williams, Sandeep Tyagi, Charles A. Peloquin, Andrew Vernon, William R. Bishai, J Grosset, Eric Nuermberger	2006	66
12	Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis American Journal of Respiratory and Critical Care Medicine ·William J. Burman, Stefan Goldberg, John L. Johnson, Grace Muzanye, Melissa Engle, Ann Mosher, Shurjeel Choudhri, Charles L. Daley, Sonal S. Munsiff, Zhen Zhao, Andrew Vernon, Richard E. Chaisson	2006	207
13	Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis American Journal of Respiratory and Critical Care Medicine ·Ian M. Rosenthal, Kathy N. Williams, Sandeep Tyagi, Andrew Vernon, Charles A. Peloquin, William R. Bishai, J Grosset, Eric Nuermberger	2005	42
14	Association between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and Tuberculosis Clinical Infectious Diseases ·Marc Weiner, Debra Benator, W. J. Burman, Charles A. Peloquin, Abdul Qadir Khan, Andrew Vernon, Brenda Jones, Tiara Nova Alviasari, Zhen Zhao, Thomas Hodge	2005	170
15	Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during Once-Weekly Tuberculosis Therapy American Journal of Respiratory and Critical Care Medicine ·Marc Weiner, Naomi Bock, Charles A. Peloquin, William J. Burman, Awal Khan, Andrew Vernon, Zhen Zhao, Stephen E. Weis, Timothy R. Sterling, Katherine Hayden, Stefan Goldberg	2004	62
16	Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis American Journal of Respiratory and Critical Care Medicine ·Eric Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Kathy N. Williams, Ian M. Rosenthal, Richard O’Brien, Andrew Vernon, Richard E. Chaisson, William R. Bishai, J Grosset	2004	167
17	Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine American Journal of Respiratory and Critical Care Medicine ·Marc Weiner, William J. Burman, Andrew Vernon, Debra Benator, Charles A. Peloquin, Awal Khan, Stephen E. Weis, Barbara King, Susan Adamovitz, Thomas Hodge	2003	151
18	A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment American Journal of Respiratory and Critical Care Medicine ·Naomi Bock, Timothy R. Sterling, Carol Hamilton, Bys, Yongcheng Wang, Kuntal Panwar, Ann Mosher, Mary H. Samuels, Andrew Vernon	2002	55
19	ACUTE GASTROINTESTINAL ILLNESS AND CHILD CARE ARRANGEMENTS American Journal of Epidemiology ·Cheryl Alexander, Ervinna Wahyuni, Ellen J. MacKenzie, Andrew Vernon, Guillermina Santiago Galvez	1990	60
20	Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome Gastroenterology ·Barbara E. Laughon, John J. Gach, Andrew Vernon, Thomas C. Quinn, B. Frank Polk, John F. Modlin, Robert H. Yolken, Mishelle Carolina	1988	214

About Andrew Vernon

Andrew Vernon is a scholar working on Infectious Diseases, Epidemiology, Pediatrics, Perinatology and Child Health, Speech and Hearing and Statistics and Probability, having authored 58 papers that have together received 4.7k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (39 papers), Pneumocystis jirovecii pneumonia detection and treatment (18 papers), Mycobacterium research and diagnosis (10 papers), Pneumonia and Respiratory Infections (10 papers), Infectious Diseases and Tuberculosis (8 papers), HIV/AIDS drug development and treatment (5 papers), Pharmaceutical studies and practices (5 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Infectious Diseases (3.8k citations), Epidemiology (3.0k citations), Surgery (1.8k citations), Molecular Medicine (151 citations) and Pharmacology (385 citations). Andrew Vernon has collaborated with scholars based in United States, Uganda and Canada. Frequent co-authors include John Jereb, Gerald H. Mazurek, Stefan Goldberg, William J. Burman, Kenneth G. Castro, Charles A. Peloquin, Marc Weiner, Michael F. Iademarco, Beverly Metchock and Richard E. Chaisson. Their work appears in journals such as American Journal of Respiratory and Critical Care Medicine, PLoS Medicine, Clinical Infectious Diseases, Contemporary Clinical Trials and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact